Edit
AAVantgarde Bio
https://www.aavantgardebio.com/Last activity: 03.05.2024
Probably Closed - Reference to AAVantgarde
AAVantgarde is a clinical stage, Italian-headquartered international biotechnology company with two proprietary AAV platforms for large-gene delivery
Location: Italy, Lombardy, Milan
Investors 2
| Date | Name | Website |
| 18.06.2023 | Forbion | forbion.co... |
| 15.06.2023 | Atlas Vent... | atlasventu... |
Mentions in press and media 4
| Date | Title | Description |
| 03.05.2024 | AAVantgarde presents the design of its innovative LUCE-1 trial for USH1B at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit | May 3, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the presentation of... |
| 23.04.2024 | AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting | April 23, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the publication ... |
| 06.06.2023 | AAVantgarde Bio Closes €61M Series A Financing | AAVantagarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing two proprietary Adeno-Associated Viral (AAV) vector platforms, raised €61M in Series A funding. The round was co-led by Atlas Venture and Forbion, with ... |
| - | AAVantgarde Bio | “Homepage - AAVantgarde Bio” |